FDA Panel Favors Chelsea’s Northera Drug Despite Some Reservations

An FDA advisory panel voted 7–4 with one abstention to recommend approval of Chelsea Therapeutics’ Northera, arguing a high unmet medical need outweighs safety concerns and a lack of long-term efficacy data. The drug is under review to treat low blood pressure in patients with nervous system disorders.
Washington Drug Letter